Gat Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 25-12-2024
- Paid Up Capital ₹ 1.00 M
as on 25-12-2024
- Company Age 8 Year, 3 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 1.20 M
as on 25-12-2024
About Gat Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.20 M.
Gajender Singh and Ashish Pundir serve as directors at the Company.
- CIN/LLPIN
U74999CH2016PTC041251
- Company No.
041251
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Oct 2016
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Gat Pharmaceuticals Private Limited offer?
Gat Pharmaceuticals Private Limited offers a wide range of products and services, including Pharma Franchise, Pharmaceutical Distributors, Aceclofenac Tablet, Aceclofenac Paracetamol Serratiopeptidase Tablet, Antibacterial Drugs, Ofloxacin Ornidazole Tablets, Ofloxacin Tablet IP, Pain Reliever Gel, Diclofenac Diethylamine Gel, Antihistamines.
Who are the key members and board of directors at Gat Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gajender Singh  | Director | 13-Oct-2016 | Current |
| Ashish Pundir | Director | 13-Oct-2016 | Current |
Financial Performance of Gat Pharmaceuticals.
Gat Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Gat Pharmaceuticals?
In 2017, Gat Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Syndicate Bank Creation Date: 17 Sep 2018 | ₹0.30 M | Open |
Syndicate Bank Creation Date: 20 Jan 2017 | ₹0.90 M | Open |
How Many Employees Work at Gat Pharmaceuticals?
Unlock and access historical data on people associated with Gat Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gat Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gat Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
